Global Hyperhidrosis Treatment Market, By Type (Axillary Hyperhidrosis, Palmar Hyperhidrosis, plantar Hyperhidrosis), Treatment (Oral Medications, Over the Counter Antiperspirants, Surgery, Lasers, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Hyperhidrosis Treatment Market Analysis and Size
The hyperhidrosis treatment market is expected to witness significant growth during the forecast period. Hyperhidrosis is when the patient experiences extreme sweating issues independent of environmental conditions and thermoregulatory requirements. Over-the-counter antiperspirants are often the first line of defense for excessive sweating. Botulinum toxin type A is a safe and effective treatment for focal hyperhidrosis, which lasts longer than topical treatments and does not require invasive surgical procedures.
Data Bridge Market Research analyses a growth rate in the global hyperhidrosis treatment market in the forecast period 2023-2030. The expected CAGR of global Hyperhidrosis treatment market is tend to be around 5.60% in the mentioned forecast period. The market was valued at USD 607.52 million in 2022, and it would grow upto USD 939.45 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hyperhidrosis Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Axillary Hyperhidrosis, Palmar Hyperhidrosis, plantar Hyperhidrosis), Treatment (Oral Medications, Over the Counter Antiperspirants, Surgery, Lasers, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
GSK Plc (U.K.), TheraVida (U.S.), Revance (U.S.)., NovaMedica. (Russia), Ulthera, Inc. (U.S.), DEMIRA e.V (Germany), Abbvie, Inc (U.S.), Fresh Tracks Therapeutics, Inc. (U.S.), Dr. August Wolff GmbH (Germany), Dermavant Sciences, Inc. (U.S.), Eirion Therapeutics, Inc (U.K.), Kaken Pharmaceutical Co., Ltd. (Japan), Intas Pharmaceuticals Ltd. (India), Roivant Sciences Ltd (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
Hyperhidrosis disorders are typically characterized by excessive sweating. The excess of sweat in this condition is not even certainly associated with heat or exercise; it is related or concerned to medical abnormality. The extreme sweat occurs in areas of the body such as underarms, palms, face; some people feel the sweat in their shoes and are also unrelated to body temperature. The major cause of the diseases could be the neurologic, endocrine, infectious and other systemic diseases, but healthy people are also likely to report the sufferings from Hyperhidrosis disorders.
Global Hyperhidrosis Treatment Market Dynamics
Drivers
- Increasing Strategic Partnerships
The strategic partnerships and collaborations between several market players and associations are helping in the growth of the market. For instance, in April 2021, Fortress Biotech, partner company Journey Medicals, entered into a definitive agreement to acquire Qbrexza in the USA from Dermira, a wholly-owned subsidiary of Eli Lilly. Therefore, the market is projected to witness growth. Though, the short-term results of cosmetic and therapeutic procedures are a major factor limiting the growth of the market.
- Growing R&D Activities
The latest R&D activities associated with the market are gaining attraction globally. For instance, in October 2021, Brickell Biotech Inc. reported positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies that evaluated sofpironium bromide gel, 15% as a once-daily topical formulation in patients having primary axillary hyperhidrosis. This boosts the market growth.
Opportunities
- Increase in Hyperhidrosis Cases
As per the study published in National Library of Medicine by Jared Brackenrich in October 2021, In the U.S, the incidence of this disorder is projected to be around 3%. Emotional, psychological, social, and occupational impairment can all be caused by hyperhidrosis. Thus, growing burden of hyperhidrosis expected to boost the demand for its treatment thus increase the market growth.
- Increasing Demand of Botox
According to the article published in International Hyperhidrosis Society of October 2020, Excessive sweating of the armpits, hands, feet, head, and face and other relatively small body areas can be treated with onabotulinumtoxin A. Botox has been shown to reduce sweating by 82-87%. The effects begin to show up 2 to 4 days post treatment, with the full effects generally appearing within two weeks. Dryness lasts 4 to 12 months on average, but few studies have found that it can last up to 14 months.
Restraints/Challenges
- Side Effects of Botox
Several side effects are associated with botox. Effects such as muscle weakness, vision problems, breathing problems that are deeply affecting the patients and thus hampering the market growth.
- High Cost
The huge expenditure of the treatment methods impede the market growth. Many times, due to lack of inappropriate payment plans and special considerations by the organizations, the patients fail to adapt these high-end treatment options which in return cost heavy impact on their health. Thus, this is an important restrain that needs to be taken care of.
This global hyperhidrosis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global Hyperhidrosis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Hyperhidrosis Treatment Market
COVID-19 had a neutral impact on the market growth. According to the January 2021 published article titled, Paroxysmal hypothermia and hyperhidrosis with exacerbation after COVID‑19 infection, periods of hypothermia alternated with fever for four days. Although, after the recovery phase, episodic hyperhidrosis and hypothermia continued without fever despite the use of clonidine. Therefore, the demand for hyperhidrosis treatment has increased. According to the International Hyperhidrosis Society in May 2021, sweat could actually help prevent the transmission of COVID-19. Even in the post-pandemic era, the disease and its associated treatment continue rapidly.
Recent Development:
- In May 2022, Meruho launched Rapifort Wipes in Japan, used for the treatment of primary axillary hyperhidrosis. It is the first prescription wipe preparation in the country.
- In August 2021, Brickell Biotech, Inc. stated that the final patient had completed the Phase 3 pivotal Cardigan II study, which evaluates sofpironium bromide gel, 15% in patients with primary axillary hyperhidrosis
Global Hyperhidrosis Treatment Market Scope
The global hyperhidrosis treatment market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Axillary Hyperhidrosis
- Palmar Hyperhidrosis
- Plantar Hyperhidrosis
Treatment
- Oral Medications
- Anticholinergics
- Others
- Over the Counter Antiperspirants
- Surgery
- Lasers
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Hyperhidrosis Treatment Market Regional Analysis/Insights
The global hyperhidrosis treatment market is analysed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global Hyperhidrosis treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to favorable healthcare infrastructure, high per capita income, and high rate of adoption of advanced surgeries in the region.
Asia-Pacific dominates the market due to the promotion of research & development activities and awareness.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hyperhidrosis Treatment Market Share Analysis
The global hyperhidrosis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hyperhidrosis treatment market.
Key players operating in the global hyperhidrosis treatment market include:
- GSK Plc (U.K.)
- TheraVida (U.S.)
- Revance (U.S.)
- NovaMedica. (Russia)
- Ulthera, Inc. (U.S.)
- DEMIRA e.V (Germany)
- Abbvie, Inc (U.S.)
- Fresh Tracks Therapeutics, Inc. (U.S.).
- Dr. August Wolff GmbH (Germany)
- Dermavant Sciences, Inc. (U.S.)
- Eirion Therapeutics, Inc (U.K.)
- Kaken Pharmaceutical Co., Ltd. (Japan)
- Intas Pharmaceuticals Ltd. (India)
- Roivant Sciences Ltd (Switzerland)
SKU-